Hepatorenal syndrome in patients with acute alcoholic hepatitis
Requires Subscription PDF

Keywords

mortality
terlipressin
ascites
hormony kůry nadledvin
lidé
liver transplantation
lypresin
portal hypertension
retrospective study
statistika jako téma
alkoholická hepatitida
dopamin
hemodialýza
hepatorenal syndrome
jaterní encefalopatie
jaterní insuficience
jednotky intenzivní péče
mortalita v nemocnicích
portální hypertenze
renální insuficience
retrospektivní studie
sérový albumin
výsledky a postupy - zhodnocení (zdravotní péče)

Abstract

Hepatorenal syndrome is functional kidney failure in patients with portal hypertension and ascites.

Patients: 20 patients (13 men, 7 women) with acute alcoholic hepatitis and hepatorenal syndrome type 1 were hospitalised at the Intensive Care Unit, 1st Dept. of Internal Medicine, University Hospital in Košice. All patients were treated with continual terlipressin infusion (1 mg daily, in case of low effect, dose increased to 2 mg daily) combined with albumin, mean treatment duration was 20.00 ± 11.69 days. Haemodialysis was indicated in 11 patients due to oligo-anuria with hyperhydratation, metabolic acidosis or hyperkalemia.

Results: A complete response to therapy (creatinine < 133 μmol/1) was seen in 6 patients (30%), a response to treatment (> 20% creatinine decrease) was observed in 18 patients (90%). Therapy led to an increase in natrium, diuresis and natriuresis and a decrease in serum creatinine and the Child-Pugh score. Hospital mortality was 40%. No pre-treatment parameter except for the grade of hepatic encephalopathy (serum creatinine, bilirubin and natrium, natriuresis, diuresis and Child-Pugh score) was associated with mortality, but patients who survived showed an improvement in liver functions after therapy (Child-Pugh score and bilirubin decrease).

Conclusion: Combined treatment with terlipressin and albumin improves renal functions in patients with acute alcoholic hepatitis and hepatorenal syndrome typel, however, the survival of patients depends on an improvement in liver functions during the treatment.

Gastroenterologie a hepatologie 2/2012 Gastroenterologie a hepatologie 2/2012 Gastroenterologie a hepatologie 2/2012

External Links

Requires Subscription PDF